Marshall Wace North America’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Marshall Wace North America’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$830K	Buy	+39,503	New	+$870K	﹤0.01%	986
2021 Q2	–	Sell	-55,953	Closed	-$1.63M	–	1866
2021 Q1	$1.63M	Buy	+55,953	New	+$1.57M	0.01%	888
2020 Q3	–	Sell	-22,191	Closed	-$438K	–	1542
2020 Q2	$438K	Sell	22,191 -7,591	-25%	-$145K	﹤0.01%	945
2020 Q1	$367K	Buy	+29,782	New	+$486K	﹤0.01%	817

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Marshall Wace North America's NGM Position: Q3 2021 in Review

Marshall Wace North America opened a new position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2021: 39,503 shares worth $830K. The stake represents ﹤0.01% of the portfolio and ranks #986 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in NGM as recently as Q1 2021.

Marshall Wace North America first reported a position in NGM in Q1 2020 and has held it in 4 quarters since. The position peaked at $1.63M in Q1 2021. 120 funds tracked by Wall St. Rank hold NGM as of Q3 2021.

Marshall Wace North America held 39,503 shares of NGM Biopharmaceuticals, Inc. Common Stock worth $830K as of Q3 2021.
NGM Biopharmaceuticals, Inc. Common Stock was a new Marshall Wace North America position in Q3 2021.
NGM Biopharmaceuticals, Inc. Common Stock made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #986 holding.
Marshall Wace North America first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and has held it in 4 quarters since.
Marshall Wace North America's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.63M in Q1 2021.
120 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.